|Slideshows|November 13, 2019

Treating Bipolar Depression With Atypical Antipsychotics: Pros, Cons, and Tips

Depression predominates across the lifespan in patients with bipolar disorder. Here: A discussion about (and beyond) the four FDA-approved drugs to treat symptoms.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Challenges in Bipolar Disorder: Discussion With Manish Zinzuvadia, MD

ByManish Zinzuvadia, MD

December 2nd 2025

Looking Back: Key Insights from November 2025

ByJessica Walters

November 28th 2025

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

ByAndrew Nguyen, MD, MSc,Ayal Schaffer, MD, FRCPC

November 26th 2025

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

ByJessica Walters

November 24th 2025

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Treating Bipolar Depression With Atypical Antipsychotics: Pros, Cons, and Tips

Newsletter

Related Content

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

Challenges in Bipolar Disorder: Discussion With Manish Zinzuvadia, MD

Looking Back: Key Insights from November 2025

Through the Peaks and Valleys: Assessing and Addressing Suicide Risk in Bipolar Disorder

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

What Happened to Psychopathology?

Favorable Profile Data On MK-2214 for Treatment of Alzheimer Disease

Catatonia Crisis: Navigating the IV Lorazepam Shortage